The ACHN cell line originates from metastatic sites of human renal cell adenocarcinoma, specifically from the ascites fluid of affected individuals. This cell line provides a valuable platform for deciphering the biology of metastatic renal cell adenocarcinoma and evaluating potential therapeutic interventions. The ACHN cell line showcases several molecular features and genetic alterations synonymous with advanced stages of the disease, making it highly relevant for preclinical studies aiming to understand metastatic behavior and therapeutic resistance. In vitro and in vivo assays using ACHN shed light on the disease’s aggressive progression, invasion patterns, angiogenesis, and potential responses to therapeutic agents. Researchers extensively use the ACHN model to delve into the nuances of renal cell adenocarcinoma metastasis and to test and formulate novel therapeutic strategies, particularly those addressing metastatic progression and treatment resistance.

Model Details

Cancer Location: Kidney
Cancer Type: Renal Cell Adenocarcinoma
Model Name: ACHN
Mouse Strain: CIEA NOG

ACHN Growth curves


Growth of subcutaneous ACHN in CIEA NOG mice (n=5)

Request Additional CDX Model Data


Get Started.

Have questions about how TD2 can assist with your regulatory needs? Reach out to our expert staff today to get started.